Abstract:Any variation in normal cellular function results in mitochondrial dysregulation that occurs in several diseases, including cancer. Such processes as oxidative stress, metabolism, signaling, and biogenesis play significant roles in cancer initiation and progression. Due to their central role in cellular metabolism, mitochondria are favorable therapeutic targets for the prevention and treatment of conditions like neurodegenerative diseases, diabetes, and cancer. Subcellular mitochondria-specific theranostic nanoformulations for simultaneous targeting, drug delivery, and imaging of these organelles are of immense interest in cancer therapy. It is a challenging task to cross multiple barriers to target mitochondria in diseased cells. To overcome these multiple barriers, several mitochondriotropic nanoformulations have been engineered for the transportation of mitochondria-specific drugs. These nanoformulations include liposomes, dendrimers, carbon nanotubes, polymeric nanoparticles (NPs), and inorganic NPs. These nanoformulations are made mitochondriotropic by conjugating them with moieties like dequalinium, Mito-Porter, triphenylphosphonium, and Mitochondria-penetrating peptides. Most of these nanoformulations are meticulously tailored to control their size, charge, shape, mitochondriotropic drug loading, and specific cell-membrane interactions. Recently, some novel mitochondria-selective antitumor compounds known as mitocans have shown high toxicity against cancer cells. These selective compounds form vicious oxidative stress and reactive oxygen species cycles within cancer cells and ultimately push them to cell death. Nanoformulations approved by the FDA and EMA for clinical applications in cancer patients include Doxil, NK105, and Abraxane. The novel use of these NPs still faces tremendous challenges and an immense amount of research is needed to understand the proper mechanisms of cancer progression and control by these NPs. Here in this review, we summarize current advancements and novel strategies of delivering different anticancer therapeutic agents to mitochondria with the help of various nanoformulations.

Mitochondria-targeted drug delivery system for cancer treatment.

Mitochondria-Targeted Nanomedicine for Enhanced Efficacy of Cancer Therapy

Mitochondria-Targeted Nanocarriers Promote Highly Efficient Cancer Therapy: A Review

Mitochondria-targeted cancer therapy based on functional peptides

Mitochondrial-Targeting Anticancer Agent Conjugates and Nanocarrier Systems for Cancer Treatment

[Mitochondrial Drug Delivery for Cancer Therapy].

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

Recent Advancements in Mitochondria-Targeted Nanoparticle Drug Delivery for Cancer Therapy

A sojourn on mitochondria targeted drug delivery systems for cancer: Strategies, clinical and future prospects

Multifunctional Mitochondria-Targeting Nanosystems for Enhanced Anticancer Efficacy

Recent Progress in Mitochondria-Targeted Drug and Drug-Free Agents for Cancer Therapy

Advancements in nano drug delivery system for liver cancer therapy based on mitochondria-targeting

Small Mitochondria-Targeting Molecules As Anti-Cancer Agents

Targeted Mitochondrial Nanomaterials in Biomedicine: Advances in Therapeutic Strategies and Imaging Modalities

Mitocans Revisited: Mitochondrial Targeting as Efficient Anti-Cancer Therapy

Mitochondrion-specific Dendritic Lipopeptide Liposomes for Targeted Sub-Cellular Delivery

Novel Strategies for Disrupting Cancer-Cell Functions with Mitochondria-Targeted Antitumor Drug-Loaded Nanoformulations

Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives

Mitochondria‐targeting metallodrugs for cancer therapy: perspectives from cell death modes

Application Prospects of Triphenylphosphine-Based Mitochondria-Targeted Cancer Therapy

Biological Evaluation of Mitochondria Targeting Small Molecules As Potent Anticancer Drugs.